{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:25:28Z","timestamp":1732857928658,"version":"3.30.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,28]]},"DOI":"10.7759\/cureus.74671","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T15:38:37Z","timestamp":1732808317000},"source":"Crossref","is-referenced-by-count":0,"title":["Cladribine Use in Relapsing Multiple Sclerosis After 8\u201310 Years: Two Case Reports of Patients From the ORACLE-MS Study"],"prefix":"10.7759","author":[{"given":"Miguel Angel","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossana","family":"Abreu Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yessica","family":"Contreras Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson R","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019, 26:27-40. 10.1111\/ene.13819","journal-title":"Eur J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.676686","article-title":"Memory B cells in multiple sclerosis: emerging players in disease pathogenesis","volume":"12","author":"DiSano KD","year":"2021","unstructured":"DiSano KD, Gilli F, Pachner AR. Memory B cells in multiple sclerosis: emerging players in disease pathogenesis. Front Immunol. 2021, 12:676686. 10.3389\/fimmu.2021.676686","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi G","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, et al.. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019, 29:168-74. 10.1016\/j.msard.2019.01.038","journal-title":"Mult Scler Relat Disord"},{"key":"ref4","unstructured":"Annex I. summary of product characteristics. (2017). Accessed: December 12, 2022: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00394-0","article-title":"Expert-agreed practical recommendations on the use of cladribine","volume":"11","author":"Meca-Lallana V","year":"2022","unstructured":"Meca-Lallana V, Dom\u00ednguez JMG, Ruiz RL, et al.. Expert-agreed practical recommendations on the use of cladribine. Neurol Ther. 2022, 11:1475-88. 10.1007\/s40120-022-00394-0","journal-title":"Neurol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist TP","year":"2014","unstructured":"Leist TP, Comi G, Cree BA, et al.. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014, 13:257-67. 10.1016\/S1474-4422(14)70005-5","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2055217317732802","article-title":"The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study","volume":"3","author":"Freedman MS","year":"2017","unstructured":"Freedman MS, Leist TP, Comi G, et al.. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study. Mult Scler J Exp Transl Clin. 2017, 3:2055217317732802. 10.1177\/2055217317732802","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson AJ","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al.. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018, 17:162-73. 10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420922685","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)","volume":"13","author":"Patti F","year":"2020","unstructured":"Patti F, Visconti A, Capacchione A, Roy S, Trojano M. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020, 13:1756286420922685. 10.1177\/1756286420922685","journal-title":"Ther Adv Neurol Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211049392","article-title":"Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study","volume":"28","author":"Giovannoni G","year":"2022","unstructured":"Giovannoni G, Singer BA, Issard D, Jack D, Vermersch P. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study. Mult Scler. 2022, 28:1219-28. 10.1177\/13524585211049392","journal-title":"Mult Scler"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01865-w","article-title":"Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5\u00a0mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies","volume":"38","author":"Giovannoni G","year":"2021","unstructured":"Giovannoni G, Comi G, Rammohan K, et al.. Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5\u00a0mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies. Adv Ther. 2021, 38:4975-85. 10.1007\/s12325-021-01865-w","journal-title":"Adv Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni G","year":"2023","unstructured":"Giovannoni G, Boyko A, Correale J, et al.. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY extension cohort of CLASSIC-MS: an ambispective study. Mult Scler. 2023, 29:719-30. 10.1177\/13524585231161494","journal-title":"Mult Scler"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231183221","article-title":"Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4","volume":"16","author":"Centonze D","year":"2023","unstructured":"Centonze D, Amato MP, Brescia Morra V, et al.. Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4. Ther Adv Neurol Disord. 2023, 16:17562864231183221. 10.1177\/17562864231183221","journal-title":"Ther Adv Neurol Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103755","article-title":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","volume":"61","author":"Rauma I","year":"2022","unstructured":"Rauma I, Viitala M, Kuusisto H, et al.. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord. 2022, 61:103755. 10.1016\/j.msard.2022.103755","journal-title":"Mult Scler Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2106783","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4","volume":"23","author":"Meuth SG","year":"2022","unstructured":"Meuth SG, Bayas A, Kallmann B, et al.. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opin Pharmacother. 2022, 23:1503-10. 10.1080\/14656566.2022.2106783","journal-title":"Expert Opin Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.02.018","article-title":"Potential mechanisms of action related to the efficacy and safety of cladribine","volume":"30","author":"Baker D","year":"2019","unstructured":"Baker D, Pryce G, Herrod SS, Schmierer K. Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019, 30:176-86. 10.1016\/j.msard.2019.02.018","journal-title":"Mult Scler Relat Disord"},{"key":"ref17","article-title":"Regulatory T cells and B cells: implication on autoimmune diseases","volume":"6","author":"Wang P","year":"2013","unstructured":"Wang P, Zheng SG. Regulatory T cells and B cells: implication on autoimmune diseases. Int J Clin Exp Pathol. 2013, 6:2668-74.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref18","unstructured":"Blood biomarker dynamics in highly active relapsing multiple sclerosis patients treated with cladribine tablets. results of the 2-year MAGNIFY-MS study. (2023). https:\/\/www.cladribinetabletsinfo.global\/content\/dam\/web\/healthcare\/cladribinetabletsinfo\/images\/update-06-03\/wiendl-...."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook S","year":"2019","unstructured":"Cook S, Leist T, Comi G, et al.. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019, 29:157-67. 10.1016\/j.msard.2018.11.021","journal-title":"Mult Scler Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.763433","article-title":"Integrated lymphopenia analysis in younger and older patients with multiple sclerosis treated with cladribine tablets","volume":"12","author":"Giovannoni G","year":"2021","unstructured":"Giovannoni G, Coyle PK, Vermersch P, et al.. Integrated lymphopenia analysis in younger and older patients with multiple sclerosis treated with cladribine tablets. Front Immunol. 2021, 12:763433. 10.3389\/fimmu.2021.763433","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/273549-cladribine-use-in-relapsing-multiple-sclerosis-after-8-10-years-two-case-reports-of-patients-from-the-oracle-ms-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T15:38:39Z","timestamp":1732808319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/273549-cladribine-use-in-relapsing-multiple-sclerosis-after-8-10-years-two-case-reports-of-patients-from-the-oracle-ms-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.74671","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,28]]}}}